Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25190745 | 0.95 | GAA (0.47) | HDAC3HDAC8HDAC6GAARAB9A | |
| SCHEMBL25189127 | 0.91 | RORC (0.42) | HDAC3HDAC8HDAC6GAARAB9A | |
| SCHEMBL25190807 | 0.90 | HDAC3 (0.39) | HDAC3HDAC8HDAC6ACACBGAA | |
| SCHEMBL25213787 | 0.89 | TRPV1 (0.44) | HDAC3HDAC8HDAC6RORCEPHX2 | |
| SCHEMBL25183896 | 0.83 | NR1H4 (0.46) | NR1H4EPHX2CA1CA2TRPV1 | |
| SCHEMBL25190146 | 0.82 | EPHX2 (0.46) | HDAC3HDAC8HDAC6ACACBGAA | |
| SCHEMBL25194563 | 0.81 | RIPK1 (0.44) | HDAC3HDAC8HDAC6RORCNR1H4 | |
| SCHEMBL25183890 | 0.78 | RIPK1 (0.46) | HDAC8HDAC6RAB9ANR1H4EPHX2 | |
| SCHEMBL25189606 | 0.78 | RORC (0.39) | HDAC3HDAC8HDAC6RORCNR1H4 | |
| SCHEMBL25213796 | 0.77 | RIPK1 (0.62) | RORCNR1H4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| CN-115151252-A | Iron death inhibitors diarylamine para-acetamides | 维泰瑞隆有限公司 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | HDAC3 1396/4885HDAC8 1707/4885HDAC6 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.